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r Vallieres (Seattle, Wash). Dr Veronesi, thank you for this
eview and for sending me all the material way ahead of time. That
as appreciated.
In this retrospective review covering 124 patients over a period
f 7 years, I think you have convincingly shown that the presence
f nodal metastasis in patients undergoing pulmonary metastasec-
omy carries a dismal prognosis, as others have previously sug-
ested but generally with less numerous series. From your survival
ata, it appears that the role of pulmonary metastasectomy is
robably limited to nonexistent in the presence of N2 disease.
our article brings 2 issues to discuss relating the role of nodal
ampling or dissection: first, the staging issues, and second, the
otential of any therapeutic issue of removing lymph nodes at the
ime of pulmonary metastasectomy.
First I’d like you to address a few questions regarding the
taging issue. Considering your data and a 0% 5-year survival in
atients with N2 disease, what is your practice now? Do you
ecommend routine mediastinal staging with mediastinoscopy de-
pite normal imaging? Do you restrict that only for patients with
reast, gynecologic, melanoma, or germ cell tumor primaries?
hat do you do now in Milan for these patients?
Dr Veronesi. One limitation of the study was that the role of PET
can was not well indicated in this series, but in a previous work I
ersonally analyzed the role of PET scan in lung metastasectomy and
ound that most N-positive patients were identified at PET scan. In
hat series we excluded some patients with nodal involvement because q
72 The Journal of Thoracic and Cardiovascular Surgery ● Aprif the PET scan, but I think that, as was recently reported in patients
ith lung cancer, PET with its high negative predictive value will be
ble to limit the role of mediastinoscopy. So in case of a PET-negative
ediastinum with a computed tomography contrast negative at that
evel, we do not use mediastinoscopy. In the case of PET-positive
ediastinum, I think the mediastinoscopy is a good tool to exclude
isease at that level. The problem of N1 disease remains because both
ET and mediastinoscopy are not precise tools to evaluate this level
f disease, so in these cases I think that thoracotomy is the only
ossibility.
Dr Vallieres. You showed that there was no survival difference
elating to the size of the metastases. What about the presence or
bsence of nodal involvement correlating to the size of the metastases?
Dr Veronesi. We did not find a significant correlation between
odal involvement and size of metastasis. However, we found that the
esion larger than 4 mm had a prevalence rate of nodal involve-
ent of 30% more than smaller lesions, so it may suggest that in
arge lesions such as this, larger than 4, sampling should be made.
Dr Vallieres. Do you mean 4 mm or 4 cm?
Dr Veronesi. Centimeters.
Dr Vallieres. As you have stated in your discussion by doing
n atypical resection, either a wedge or a tumorectomy, we under-
tage many of the patients. Would you thus advocate that we now
outinely stage N1 and N2 nodes when we are doing a video-
ssisted thoracic surgery wedge or an open-wedge metastasec-
omy?
Dr Veronesi. I am not convinced that in all cases we have to do
ampling or dissection (radical lymph node dissection). Maybe in a
mall lesion, a peripheral PET-negative metastasis, maybe from a
atient with sarcoma, we can avoid lymph node sampling because
here are some other disadvantages to this procedure, such as difficult
o redo a thoracotomy, for example, for recurrent metastasis.
Dr Vallieres. I’d like to explore the therapeutic role of nodal
issection/resection. Your data suggest that nodal sampling or
issection in these patients definitely allows for better staging of
heir disease. Is there also a potential therapeutic effect, benefit, of
odal dissection versus sampling in this scenario of metastasec-
omy? Did you look at the survival difference in patients with
ode-positive disease, whether they’d had a nodal dissection ver-
us just sampling? I understand that the numbers are small.
Dr Veronesi. We performed a separate analysis in the popu-
ation evaluating the role of radical versus sampling lymph nodes
issection, and no difference was found. Even regarding . . . (end
f cassette).
Dr Vallieres. During the study period did you perform medi-
stinoscopies in patients who had clinical N disease and as such
liminate these patients from the cohort you have just presented?
f you did, did you look at the survival of the individuals in whom
ou had identified N2 disease and did not operate versus those who
ere found to have N2 disease at surgery? Did they behave the
ame, or did the metastasectomy have an impact?
Dr Veronesi. This is a good question. We certainly performed
ediastinoscopy and excluded patients from surgery, but I have no
ata about their survival outcome.
Dr Vallieres. I enjoyed your presentation. I certainly encour-
ge you and your colleagues in Milan in continuing to prospec-
ively accrue information on these patients so that some of these
uestions will be answered in the future.
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